Supplementary Data from BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage–Inducible Gene

Autor: D. Paul Harkin, Peter H. Watson, Patrick G. Johnston, George Reid, Paul B. Mullan, Patrick J. Morrison, Tong F. Lioe, Ethan D. Emberley, Karl Mulligan, Stephen Moore, Colin R. James, Gail E. Stewart, Jennifer E. Quinn, Julia J. Gorski, Richard D. Kennedy

Supplementary Data from BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage–Inducible Gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71294171ef069218458768d924db819f
https://doi.org/10.1158/0008-5472.22364252

Abstract P1-10-17: cGAS-STING driven immune activation predicts response to neoadjuvant chemotherapy and suggests rational IO combination therapies: Results of the Neo-DDIR study

Autor: Stephen J Kirk, Gemma E Logan, Steven Walker, Tong Lioe, Stuart McIntosh, Jane Hurwitz, Paul Harkin, Colin R. James, Richard D Kennedy, Laura A. Knight, Kienan Savage, Eileen Parkes, Andrena McGavigan, Keith Lowry

Publikováno v: Cancer Research. 80:P1-10

Introduction: We previously identified an immune-driven gene expression signature recognizing loss of the Fanconi Anemia/BRCA DNA repair pathway - the DNA damage immune response (DDIR) assay. This 44-gene expression-based assay predicted response to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::62af8b16543f008d5cbd95d299e0e6fe
https://doi.org/10.1158/1538-7445.sabcs19-p1-10-17

Rechallenging with anthracyclines and taxanes in metastatic breast cancer

Autor: Susan Cleator, Vivek Misra, Jonathan Krell, Catherine Harper-Wynne, David Miles, Carlo Palmieri, Colin R. James

Publikováno v: Nature Reviews Clinical Oncology. 7:561-574

Adjuvant use of anthracycline-taxane combination therapy is an accepted strategy in the management of high-risk early-stage breast cancer. However, the introduction of this regimen raises the question of how best to manage those patients who relapse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01b158f51a72f5c483be8f5debaeeabb
https://doi.org/10.1038/nrclinonc.2010.122

Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer

Autor: Colin R. James, Olaide Raji, Steven Walker, Paul B. Mullan, Vitali Proutski, David L. Boyle, Richard D. Kennedy, Noralane M. Lindor, F. A. McDyer, Jacqueline James, Jude M. Mulligan, Eamonn J. O'Brien, Peter Kerr, Patrick G. Johnston, Manuel Salto-Tellez, Katherine E. Keating, Fergus J. Couch, Timothy Davison, Laura Hill, Steve Deharo, D. Paul Harkin, Max Bylesjö, Jennifer E. Quinn, Gareth W. Irwin

Publikováno v: Mulligan, J M, Hill, L A, Deharo, S, Irwin, G, Boyle, D, Keating, K E, Raji, O Y, McDyer, F A, O'Brien, E, Bylesjo, M, Quinn, J E, Lindor, N M, Mullan, P B, James, C R, Walker, S M, Kerr, P, James, J, Davison, T S, Proutski, V, Salto-Tellez, M, Johnston, P G, Couch, F J, Harkin, P & Kennedy, R D 2014, ' Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer ', Journal of the National Cancer Institute, vol. 106, no. 1, djt335 . https://doi.org/10.1093/jnci/djt335
JNCI Journal of the National Cancer Institute

Most chemotherapy regimens used for breast cancer in the adjuvant, neoadjuvant, or advanced settings contain agents that directly damage DNA, such as anthracyclines (epirubicin or doxorubicin) and alkylating agents (cyclophosphamide). Approximately 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c71eef449e92d259667c57c0000edd00
https://doi.org/10.1093/jnci/djt335

Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome

Autor: Tamerlan Babayev, Susan Cleator, Angela Chow, Andreas Makris, Robert Leonard, Jonathan Krell, Deep Shah, Colin R. James, Andrew Cowdray, Adrian Lim, Riz Ahmad, Carlo Palmieri, Peter Madden, Ondrej Gojis, Pippa Riddle

Publikováno v: Clinical breast cancer. 11(3)

Background The purpose of this study is to evaluate the response to and benefit of first-line metastatic treatment (including re-exposure to trastuzumab) for patients relapsing after exposure to adjuvant trastuzumab (AT). Patients and Methods All HER

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ba93b05c53722c70b0e2f368cee078a
https://pubmed.ncbi.nlm.nih.gov/21665135